Fresh analysis reveals that patients who discontinue new weight-loss injections like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who end conventional diet and exercise regimens.
Research printed in a major medical journal demonstrates that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month once they quit.
"People buying these treatments should be cognizant of the potential of rapid rebound weight gain when the therapy is stopped," warns expert Dr. Susan Jebb.
This pace of recovery means a return to starting weight within about 18 months.
Weighing Treatments
The study, which looked at dozens of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with older methods.
Scientists point out that people who lose weight through dieting typically see a less rapid creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Experts suggest the way of the jabs accounts for the accelerated weight return.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the system to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement results in hunger is no longer kept in check, making excessive eating far more likely."
A Chronic Issue?
The NHS advise the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, due to the significant potential of weight regain, the therapy might need to be long-term.
This opinion is supported by drug manufacturers, who note that the results "highlight the long-term nature of excess weight," akin to managing diseases like high blood pressure.
User Testimonies
People who have discontinued the medication report a powerful return of appetite.
"I experienced a trigger activating and you're instantly ravenous," described a patient.
This challenge is compounded if individuals have not adopted sustainable lifestyle or habit changes during therapy.
Significant Interest
Figures suggest that millions of adults in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while the jabs are potent tools for shedding pounds, they are not a magic fix and long-term success likely depends on combined behavioural support.
